US 2026/0098092 A1Published application

Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

AssigneeChulalongkorn University

InventorsTrairak Pisitkun, Chatikorn Boonkrai, Tossapon Wongtangprasert, Tanapati Phakham, Thittaya Audomsun, Chadaporn Attakitbancha, Pijitra Saelao

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to antibodies and anti-gen-binding fragments that bind specifically to the human programmed cell death protein 1 (PD-1) and methods for treating cancer or other diseases with said antibodies and antigen-binding fragments.

Claims45

Dependent claims

An anti-PD-1 antibody or antigen-binding fragment thereof comprising:

(a) (i) a VH comprising a CDR1 comprising the sequence X1YDII (SEQ ID NO:
228), wherein X1 is T or V, a CDR2 comprising the sequence VIWTGGDTX2YNSAFMS (SEQ ID NO:
229), wherein X2 is N, W or T, and a CDR3 comprising the sequence DWX3Y (SEQ ID NO:
230), wherein X3 is A, I or M;
and (ii) a VL comprising a CDR1 comprising the sequence RASESVDNX4GNSFIQ (SEQ ID NO:
231), wherein X4 is Y or W, a CDR2 comprising the sequence FASX5LQS (SEQ ID NO:
232), wherein X5 is N, Y, H or Q, and a CDR3 comprising the sequence HQNNEDPFT (SEQ ID NO:
227);
(b) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
162, a CDR2 comprising the sequence set forth in SEQ ID NO:
163, and a CDR3 comprising the sequence set forth in SEQ ID NO:
164;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
180, a CDR2 comprising the sequence set forth in SEQ ID NO:
181, and a CDR3 comprising the sequence set forth in SEQ ID NO:
182;
(c) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
81, a CDR2 comprising the sequence set forth in SEQ ID NO:
82, and a CDR3 comprising the sequence set forth in SEQ ID NO:
83;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
85, a CDR2 comprising the sequence set forth in SEQ ID NO:
86, and a CDR3 comprising the sequence set forth in SEQ ID NO:
87;
(d) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
89, a CDR2 comprising the sequence set forth in SEQ ID NO:
90, and a CDR3 comprising the sequence set forth in SEQ ID NO:
91;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
93, a CDR2 comprising the sequence set forth in SEQ ID NO:
94, and a CDR3 comprising the sequence set forth in SEQ ID NO:
95;
(e) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
97, a CDR2 comprising the sequence set forth in SEQ ID NO:
98, and a CDR3 comprising the sequence set forth in SEQ ID NO:
99;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
101, a CDR2 comprising the sequence set forth in SEQ ID NO:
102, and a CDR3 comprising the sequence set forth in SEQ ID NO:
103;
(f) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
113, a CDR2 comprising the sequence set forth in SEQ ID NO:
114, and a CDR3 comprising the sequence set forth in SEQ ID NO:
115;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
117, a CDR2 comprising the sequence set forth in SEQ ID NO:
118, and a CDR3 comprising the sequence set forth in SEQ ID NO:
119;
or
(g) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
121, a CDR2 comprising the sequence set forth in SEQ ID NO:
122, and a CDR3 comprising the sequence set forth in SEQ ID NO:
123;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
125, a CDR2 comprising the sequence set forth in SEQ ID NO:
126, and a CDR3 comprising the sequence set forth in SEQ ID NO:
127.

54 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/114,741Filed 4 Oct 2023
Priority: 5 Oct 2022
Published: 9 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Family

Application63/378,472Us provisional application · filed 5 Oct 2022
US 2026/0098092 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

An anti-PD-1 antibody or antigen-binding fragment thereof comprising:

(a) (i) a VH comprising a CDR1 comprising the sequence X1YDII (SEQ ID NO:
228), wherein X1 is T or V, a CDR2 comprising the sequence VIWTGGDTX2YNSAFMS (SEQ ID NO:
229), wherein X2 is N, W or T, and a CDR3 comprising the sequence DWX3Y (SEQ ID NO:
230), wherein X3 is A, I or M;
and (ii) a VL comprising a CDR1 comprising the sequence RASESVDNX4GNSFIQ (SEQ ID NO:
231), wherein X4 is Y or W, a CDR2 comprising the sequence FASX5LQS (SEQ ID NO:
232), wherein X5 is N, Y, H or Q, and a CDR3 comprising the sequence HQNNEDPFT (SEQ ID NO:
227);
(b) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
162, a CDR2 comprising the sequence set forth in SEQ ID NO:
163, and a CDR3 comprising the sequence set forth in SEQ ID NO:
164;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
180, a CDR2 comprising the sequence set forth in SEQ ID NO:
181, and a CDR3 comprising the sequence set forth in SEQ ID NO:
182;
(c) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
81, a CDR2 comprising the sequence set forth in SEQ ID NO:
82, and a CDR3 comprising the sequence set forth in SEQ ID NO:
83;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
85, a CDR2 comprising the sequence set forth in SEQ ID NO:
86, and a CDR3 comprising the sequence set forth in SEQ ID NO:
87;
(d) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
89, a CDR2 comprising the sequence set forth in SEQ ID NO:
90, and a CDR3 comprising the sequence set forth in SEQ ID NO:
91;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
93, a CDR2 comprising the sequence set forth in SEQ ID NO:
94, and a CDR3 comprising the sequence set forth in SEQ ID NO:
95;
(e) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
97, a CDR2 comprising the sequence set forth in SEQ ID NO:
98, and a CDR3 comprising the sequence set forth in SEQ ID NO:
99;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
101, a CDR2 comprising the sequence set forth in SEQ ID NO:
102, and a CDR3 comprising the sequence set forth in SEQ ID NO:
103;
(f) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
113, a CDR2 comprising the sequence set forth in SEQ ID NO:
114, and a CDR3 comprising the sequence set forth in SEQ ID NO:
115;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
117, a CDR2 comprising the sequence set forth in SEQ ID NO:
118, and a CDR3 comprising the sequence set forth in SEQ ID NO:
119;
or
(g) (i) a VH comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
121, a CDR2 comprising the sequence set forth in SEQ ID NO:
122, and a CDR3 comprising the sequence set forth in SEQ ID NO:
123;
and (ii) comprising a VL comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
125, a CDR2 comprising the sequence set forth in SEQ ID NO:
126, and a CDR3 comprising the sequence set forth in SEQ ID NO:
127.

54 more elements

Facts

Application

19/114,741Filed 4 Oct 2023

Priority

5 Oct 2022

Published

9 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered